# 💊 Medical Management

## 🎯 Precision Pharmacotherapy Approach

The [2025 hypertension guideline](https://pubmed.ncbi.nlm.nih.gov/40811497/) supports initial combination treatment for stage 2 hypertension. Select agents and follow-up according to blood pressure, comorbidities, tolerability, and patient preferences.

### 📋 Evidence-Based Treatment Algorithm

1️⃣

#### Risk Assessment & Treatment Threshold

**PREVENT calculator ≥7.5%:** Initiate medication for Stage 1 HTN (130-139/80-89 mmHg)

**Stage 2 HTN (≥140/90 mmHg):** Immediate medication regardless of cardiovascular risk

2️⃣

#### First-Line Agent Selection

**Class 1 Options:** Thiazide-type diuretics (chlorthalidone preferred), long-acting dihydropyridine CCBs, ACE inhibitors, ARBs

**Stage 1 HTN:** Monotherapy initiation acceptable

3️⃣

#### Stage 2 HTN: Initial Dual Therapy

**Class 1 Recommendation:** Start two agents simultaneously from different classes

**Single-pill combinations preferred:** 20-25% better adherence, equivalent efficacy

4️⃣

#### Target Achievement & Intensification

**2025 AHA/ACC and ADA Standards of Care:** \<130/80 mmHg.

**KDIGO 2021 (Blood Pressure in CKD):** suggests a target systolic \<120 mmHg when tolerated, using standardized office measurement (grade 2B, driven by the CKD subgroup of SPRINT). It explicitly excludes kidney transplant recipients and patients on dialysis.

**Why the two numbers differ:** much of the gap is measurement technique rather than disagreement about physiology. KDIGO's lower number presumes a standardized or unattended reading, which most routine clinic cuffs do not meet.

## 💊 First-Line Antihypertensive Agents

#### 💧 Thiazide-Type Diuretics

##### Preferred Agent:

**Chlorthalidone 12.5-25 mg daily**\
Superior potency and duration vs hydrochlorothiazide

###### Mechanism & Benefits:

- Volume depletion → vasodilation
- Stroke prevention superior
- Heart failure risk reduction
- Cost-effective

###### Monitoring:

Electrolytes, creatinine at 2-4 weeks. Watch for hypokalemia, hyponatremia, hyperuricemia.

#### 🔴 Calcium Channel Blockers

##### Preferred Agents:

**Amlodipine 2.5-10 mg daily**\
**Nifedipine XL 30-90 mg daily**\
Long-acting dihydropyridines only

###### Clinical Advantages:

- Excellent stroke prevention
- No metabolic effects
- Safe in diabetes, CKD
- Complementary to RAAS inhibition

###### ⚠️ Common Side Effects:

Peripheral edema (dose-dependent), gingival hyperplasia. Avoid immediate-release formulations.

#### 🫀 RAAS Inhibitors

##### Agent Selection:

**ACE inhibitors:** Lisinopril, enalapril (dry cough 10-15%)\
**ARBs:** Losartan, valsartan (better tolerance profile)

###### Compelling Indications:

- Diabetes with any albuminuria
- Chronic kidney disease
- Heart failure with reduced EF
- Post-myocardial infarction

###### ❌ Class 3 (Harm): Dual RAAS Blockade

Never combine ACE inhibitor + ARB or + direct renin inhibitor. Increased hyperkalemia, hypotension, AKI without CV benefit.

### 🤝 Initial Combination Therapy Advantages

#### ⏱️ Time to Target

Target BP achieved **6 months faster** than sequential monotherapy titration. Earlier control reduces cardiovascular events.

#### 📊 Efficacy

Additive BP reduction from complementary mechanisms. **Lower doses** of individual agents reduce side effects.

#### 💊 Adherence

Single-pill combinations improve adherence by **20-25%** compared to multiple separate tablets.

#### ⚡ Tolerability

Fewer discontinuations due to adverse events. Complementary side effect profiles offset individual drug limitations.

### 🎯 Intensive Blood Pressure Targets

#### 📈 SPRINT Trial Evidence

##### 🫀 CV Events

**25% relative risk reduction** with intensive treatment (\<120 vs \<140 mmHg)

##### 💀 Mortality

**27% reduction** in all-cause mortality with intensive targets

##### 🧠 Cognitive

**19% reduction** in mild cognitive impairment (SPRINT-MIND)

#### ⚠️ Patient Selection for Intensive Targets

##### ✅ Appropriate Candidates

- Age 50+ years with CV risk factors
- No diabetes, stroke, or polycystic kidney disease
- Standing SBP ≥110 mmHg
- Life expectancy \>3 years
- Motivated, adherent patients

##### ❌ Avoid Intensive Targets

- Frail elderly patients
- Orthostatic hypotension
- Multiple falls history
- Limited life expectancy
- Advanced kidney disease

## 📊 Evidence Base for First-Line Agents

| Drug Class | Major Outcome Trials | Primary Benefits | Preferred Populations |
|----|----|----|----|
| **Thiazide Diuretics** | SHEP, ALLHAT, HYVET | Stroke prevention, heart failure reduction, cost-effective | Elderly, heart failure, stroke prevention |
| **ACE Inhibitors** | HOPE, EUROPA, ADVANCE | MI prevention, nephroprotection, mortality reduction | Diabetes, CKD, post-MI, heart failure |
| **ARBs** | LIFE, VALUE, ONTARGET | Stroke prevention, nephroprotection, better tolerance | ACE inhibitor intolerance, diabetes, CKD |
| **Calcium Channel Blockers** | ALLHAT, ASCOT, VALUE | Stroke prevention, elderly efficacy, no metabolic effects | Elderly, isolated systolic HTN, diabetes |

## 📚 Sources

1.  **Whelton PK, Carey RM, Aronow WS, et al.** 2017 ACC/AHA Guideline for High Blood Pressure in Adults. *Hypertension.* 2018;71(6):e13-e115. [PMID: 29133356](https://pubmed.ncbi.nlm.nih.gov/29133356/).
2.  **Cameron NA, Jones DW, Khan SS, Lloyd-Jones DM.** Case-Based Applications of the 2025 AHA/ACC/Multispecialty High Blood Pressure Guideline. *Hypertension.* 2025;82(12):2055-2063. [PMID: 41204807](https://pubmed.ncbi.nlm.nih.gov/41204807/).
3.  **Brown C, Clark D, Jones DW.** Updates in the 2025 AHA/ACC Hypertension Guideline. *Curr Hypertens Rep.* 2026;28(1). [PMID: 41843050](https://pubmed.ncbi.nlm.nih.gov/41843050/).
4.  **Ettehad D, Emdin CA, Kiran A, et al.** Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet.* 2016;387(10022):957-967. [PMID: 26724178](https://pubmed.ncbi.nlm.nih.gov/26724178/).
5.  **SPRINT Research Group.** A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med.* 2015;373(22):2103-2116. [PMID: 26551272](https://pubmed.ncbi.nlm.nih.gov/26551272/).
6.  **ALLHAT Officers.** Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or CCB vs diuretic. *JAMA.* 2002;288(23):2981-2997. [PMID: 12479763](https://pubmed.ncbi.nlm.nih.gov/12479763/).

### 🎯 Medical Management: Key Learning Points

#### 💊 First-Line Selection

- Four drug classes with outcome evidence
- Chlorthalidone preferred over HCTZ
- Long-acting CCBs only (no immediate-release)
- Never combine ACE inhibitor + ARB

#### 🤝 Combination Therapy

- Class 1 for Stage 2 HTN initial treatment
- Single-pill combinations improve adherence
- Target achieved 6 months faster
- Lower individual drug doses reduce side effects

#### 🎯 Intensive Targets

- SPRINT: \<120 mmHg reduces CV events 25%
- Careful patient selection essential
- Avoid in frail elderly or limited life expectancy
- Monitor for hypotension and falls

📚 For Educational Purposes Only

© 2025 University of Dubuque PA Program - All Rights Reserved


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/medical-management-updated.html) · Markdown synchronized October 3, 2026.